• Active, not recruiting

NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Len and Dex NDMM

Updated: Sep 7


NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Elo-KRd

Elo-KRD - University of Chicago MRD

NCT02969837: Phase 2 - Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma


This study will be a multi-center, open-label, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy will be eligible for enrollment. A total of 55 subjects will be enrolled. Time to progression or death will be calculated from the date of first treatment on protocol until the date of disease progression or death from any cause. Patients can expect to participate between 12-24 cycles. The primary endpoint will be the rate of response by next generation gene sequencing at the end of 8 cycles among non-transplant candidates and transplant candidates who agreed to defer transplant.


Sponsor:

University of Chicago


Collaborators:

Bristol-Myers Squibb

Amgen

Multiple Myeloma Research Foundation

 

ClinicalTrials.gov Identifier: NCT02969837

Official Title: Open-label, Single-arm, Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy

First Posted: November 21, 2016


Click here for details on ClinicalTrials.gov

 

Elotuzumab : National Cancer Institute

Elotuzumab : MedlinePlus Drug Information


Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

 

Drug: Elotuzumab

Drug: Carfilzomib

Drug: Lenalidomide

Drug: Dexamethasone


MRD Testing

Adaptive Biotechnologies


Multiple Myeloma Research Consortium

 

Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM)

Journal of Clinical Oncology;2021 ASCO Annual Meeting

Click here for details

 

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study

JAMA Oncol;2022 Ju

Click here for details

 

Location

United States, Illinois

United States, Michigan




Posts Archive